This article is over 9 years old

Business

Loss Of Private Funding Batters Life Sciences Sector

A drop in venture capital funding could hurt Houston’s burgeoning life sciences sector.

Listen

To embed this piece of audio in your site, please use this code:

<iframe src="https://embed.hpm.io/84943/41294" style="height: 115px; width: 100%;"></iframe>
X

Nationwide, venture capital investments in the life sciences industries fell by 14% in 2012 compared to 2011. That represents a drop of more than $1 billion in private funding. Fewer than a 140 such companies received venture capital funding last year, the lowest level since 1995.

Tracy Lefteroff of Pricewaterhouse Coopers says the loss of funding could hurt the development of everything from pharmaceuticals to medical devices.

“If you look at where the new product pipelines are, it’s coming from young venture-backed companies that then either are either acquired by the larger company or actually take the product to market themselves.”

Lefteroff notes the largest expense for a biotech company is payroll.  He says the loss of funding could hurt employment in life sciences clusters all over the country, including Houston.

Subscribe to Today in Houston

Fill out the form below to subscribe our new daily editorial newsletter from the HPM Newsroom.

* required

Andrew Schneider

Andrew Schneider

Politics and Government Reporter

Andrew heads Houston Public Media's coverage of national, state, and local elections. He also reports on major policy issues before the Texas Legislature and county and city governments across Greater Houston. Before taking up his current post, Andrew spent five years as Houston Public Media's business reporter, covering the oil...

More Information